Port Erin Biopharma Investments Ltd Net Asset Value(s) (9138E)

TIDMPEBI

RNS Number : 9138E

Port Erin Biopharma Investments Ltd

22 July 2016

Port Erin Biopharma Investments Limited

(the "Company")

Net Asset Value calculation to 30 June 2016

Jim Mellon, Chairman, commented: -

"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 June 2016 was 9.28 pence per share, including un-invested cash of GBP11,985. The portfolio is valued under IFRS at bid price.

Net Assets stand at GBP2.2 million including Investments of GBP2.19 million. This quarter's NAV represents a decrease of 9.11% from the previous valuation of 10.21 pence per share, which included un-invested cash of GBP10,713. No additional management fee is due to Shellbay Investments Limited.

 
                                                     Unaudited to 30 June 2016 GBP 
Fixed Assets 
 Investments                                                             2,187,075 
Current Assets 
 Sundry Debtors                                                              7,335 
 Uninvested cash                                                            11,985 
Current Liabilities 
 Creditors: amounts due                                                   (54,197) 
                                                     ----------------------------- 
                                                                         2,152,198 
Capital and Reserves 
 Share Capital                                                                  23 
 Share Premium                                                           1,890,142 
 Reserves                                                                  262,033 
                                                     ----------------------------- 
                                                                         2,152,198 
 
Shares in Issue                                                         23,195,558 
 
Net Asset Value per share                                               9.28 pence

Portfolio Details

 
 Investments as at 30              Value  % of Total Portfolio 
  June 2016 
-------------------------  -------------  -------------------- 
 
 Magna Biopharma Income 
  Fund                      GBP1,231,912                 56.3% 
 Regent Pacific Group         GBP249,594                 11.4% 
 Summit Corporation           GBP218,291                 10.0% 
 Other quoted holdings         GBP85,407                  3.9% 
 Other unquoted holdings      GBP401,871                 18.4% 
 
 Total                      GBP2,187,075                100.0% 
-------------------------  -------------  --------------------

For further information, please contact:

 
Port Erin Biopharma     Northland Capital   Peterhouse Capital 
 Investments Limited     Partners Limited    Limited 
The Company             Nomad and Broker    Joint Broker 
 
Denham Eke              Matthew Johnson     Lucy Williams 
 (+44) (0) 1624 639396   / David Hignell     (+44) (0) 207 469 
                         (+44) (0) 203 861   0936 
                         6625

This information is provided by RNS

The company news service from the London Stock Exchange

END

NAVFMGZNKMMGVZM

(END) Dow Jones Newswires

July 22, 2016 02:00 ET (06:00 GMT)

Agronomics (LSE:ANIC)
Historical Stock Chart
From Apr 2024 to May 2024